Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: An Eastern Cooperative Oncology Group trial (E3493)

Blood

Volumn 100, Issue 5, 2002, Pages 1634-1640

  Sparano, Joseph A ^{a,b,c,d,e,f,g,h}   Weller, Edie ^{a,b,c,d,e,f,g}   Nazeer, Tipu ^{a,b,c,d,e,f,g}   Habermann, Thomas ^{a,b,c,d,e,f,g}   Traynor, Ann E ^{a,b,c,d,e,f,g}   Manalo, Jane ^{a,b,c,d,e,f,g}   Cassileth, Peter ^{a,b,c,d,e,f,g}  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Eastern Cooperative Oncology Group   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e MAYO CLINIC   (United States)

^f NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL COUNT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036720778     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.5.1634.h81702001634_1634_1640     Document Type: Article

References (45)

1. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines
2. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay
3. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo
4. Intermittent continuous IV infusion of high-dose cyclophosphamide for remission induction in acute lymphocytic leukemia
5. Effective treatment of advanced multiple myeloma refractory to alkylating agents
6. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer
7. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule dependent effect favoring infusional administration of chemotherapy
8. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma
9. Role of doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH
10. A phase 2 trial of infusional etoposide, vincristine, and doxorubicin with bolus cyclophosphamide (EPOCH) along with filgrastim support in patients with relapsed Hodgkin's and non-Hodgkin's lymphoma
11. Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma
12. EPOCH chemotherapy for recurrent lymphoma
13. Phase 2 study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255 Cancer and Leukemia Group B
14. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV- and HTLV-I-related non-Hodgkin's lymphoma: A highly active regimen
15. Infusional cyclophosphamide, doxorubicin, and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report
16. A pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin's lymphoma
17. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma
18. Infusional cyclophosphamide, doxorubicin, and etoposide (CDE) for HIV-associated non-Hodgkin's lymphoma: Long-term follow-up and analysis of prognostic factors
19. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide (CDE)in HIV-associated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group Trial
20. Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma
21. Comparison of costs for infusion versus bolus chemotherapy administration: Analysis of five standard chemotherapy regimens in three common tumors, I: Model projections for cost based on charges
22. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage
23. A predictive model for aggressive non-Hodgkin's lymphoma
24. Primary Ki-1 anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome
25. Doxorubicin-vinblastine and doxorubicin-cyclophosphamide combination chemotherapy by continuous infusion
26. Toxicity and response criteria of the Eastern Cooperative Oncology Group
27. The use of mixture models for the analysis of survival data with long-term survivors
28. Nonparametric estimation from incomplete observations
29. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study
30. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
31. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma
32. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients
33. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group
34. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
35. Benefit of autologous bone marrow transplantation over sequential chemotherapy In poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
36. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
37. Therapy for diffuse large B-cell lymphoma: High-risk and elderly patients
38. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive lymphoma: A dose-finding pilot study
39. A phase 2 trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity
40. Mabthera (rituximab) plus CHOP is superior to CHOP in elderly patients with diffuse large B cell lymphoma: Interim results of a randomized GELA trial
41. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
42. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
43. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
44. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus the anti-CD20 monoclonal antibody rituximab in HIV-associated non-Hodgkin's lymphoma
45. Dose-adjusted EPOCH chemotherapy and rituximab: An effective regimen In poor prognosis agressive B-cell non-Hodgkin's lymphoma